Wilms Tumor Protein WT33 or WT1 Pipeline Review, H2 2018
Summary
According to the recently published report 'Wilms Tumor Protein Pipeline Review, H2 2018'; Wilms Tumor Protein WT33 or WT1 pipeline Target constitutes close to 14 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Wilms Tumor Protein WT33 or WT1 Wilms tumor protein is a protein that is encoded by the WT1 gene. It plays an important role in cellular development and cell survival. It plays an essential role for development of the urogenital system. It has a tumor suppressor as well as an oncogenic role in tumor formation. It regulates the expression of numerous target genes, including EPO.
The report 'Wilms Tumor Protein Pipeline Review, H2 2018' outlays comprehensive information on the Wilms Tumor Protein WT33 or WT1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Wilms Tumor Protein WT33 or WT1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 2 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Glioblastoma Multiforme GBM, Myelodysplastic Syndrome, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Malignant Glioma, Ovarian Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Leukemias, Pancreatic Cancer, Soft Tissue Sarcoma, Solid Tumor, Adrenal Gland Cancer, Essential Thrombocythemia, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Carcinoma, Hematological Tumor, HighGrade Glioma, Lung Cancer, Lymphoma, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional Urothelial Tract Cancer, Multiple Myeloma Kahler Disease, Neuroblastoma, NonSmall Cell Lung Cancer, Ocular Melanoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Polycythemia Vera, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Small Intestine Cancer, Testicular Cancer, Thrombocytosis, Thymic Carcinoma, Thymoma Thymic Epithelial Tumor and Transitional Cell Carcinoma Urothelial Cell Carcinoma.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Wilms Tumor Protein WT33 or WT1
The report reviews Wilms Tumor Protein WT33 or WT1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Wilms Tumor Protein WT33 or WT1 targeted therapeutics and enlists all their major and minor projects
The report assesses Wilms Tumor Protein WT33 or WT1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Wilms Tumor Protein WT33 or WT1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Wilms Tumor Protein WT33 or WT1Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Wilms Tumor Protein WT33 or WT1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope